Seres Therapeutics

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Seres Therapeutics poised for FDA approval with strong pipeline progress

Seres Therapeutics is well-positioned for potential FDA approval of SER-109, backed by strong Phase III efficacy and safety data. The company's financial stability and strategic collaborations underscore a focused approach towards commercial success. Addressing key challenges and leveraging opportunities in product development and market entry will be crucial for Seres Therapeutics' future growth.

Seres Therapeutics secures FDA approval for VOWST, eyes commercial success

Seres Therapeutics is poised for success with FDA approval of VOWST and positive study results for SER-155. The company faces challenges in ensuring consistent engraftment and optimizing operational efficiencies. Opportunities lie in commercializing VOWST and advancing microbiome therapeutics.

Seres Therapeutics reports robust Q2 earnings, eyes VOWST growth

Seres Therapeutics had a strong Q2 2023, propelled by VOWST approval and positive sales performance, positioning the company for continued growth.
While facing challenges like Medicare affordability issues and net losses, Seres remains optimistic about VOWST's potential and profitability trajectory.
By capitalizing on opportunities in education, expansion, and efficiency, Seres aims to drive VOWST adoption, enhance market presence, and achieve financial success.

Seres Therapeutics excels in Q3 with VOWST launch success

Seres Therapeutics reported a strong Q3 performance with the successful VOWST launch, despite a net loss. The company's restructuring focuses on VOWST's growth and long-term sustainability. Challenges include optimizing VOWST sales and navigating reimbursement differences.

Seres Therapeutics excels in 2023 with VOWST launch and financial focus

Seres Therapeutics had a strong 2023, marked by successful product launches, financial discipline, and promising development in microbiome therapeutics.
The company's strengths include innovation, financial stability, strong leadership, and efficient budget management, positioning them for future growth.
Challenges include sustaining momentum, securing funding for advancement, meeting regulatory expectations, and ensuring positive patient experiences.
Opportunities lie in continued growth, partnerships, strategic funding, innovation, and establishing a compelling market narrative.
Overall, Seres Therapeutics is well-positioned for success in the microbiome therapeutics market, with a focus on product development and financial discipline.

Seres Therapeutics reports robust Q1 sales and advances pipeline growth

Seres Therapeutics demonstrated strong sales performance with VOWST net sales reaching $10.1 million in Q1 2024.
The company's focus on commercialization of VOWST and advancement of microbiome therapeutic candidates like SER-155 shows promise for future growth.
Challenges in pricing, inventory management, and funding are being addressed, while opportunities in new patient populations and strategic partnerships are being explored.

Seres Therapeutics sells VOWST assets, reports strong Q2 earnings

Seres Therapeutics' Q2 performance was marked by a strategic asset sale, strong financial results, and progress in key pipeline programs. The company's focus on transformative therapies and data-driven pipeline prioritization positions it well for future growth and impact in the healthcare sector.

Seres Therapeutics reports Q3 loss but sees growth opportunities ahead

Seres Therapeutics faced a net loss in Q3 2024 but maintained strong cash reserves for operations into Q4 2025.
Positive results from SER-155 and the VOWST sale present opportunities for growth and addressing bacterial infections in patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:10 a.m. ET. An audio webcast of the panel discussion will be available under the “Investors and News” section of Seres' website.

Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication of data from its Phase 3 ECOSPOR IV trial (ClinicalTrials.gov Identifier: NCT03183128) in JAMA Network Open that reinforce previously published results from the Phase 3 ECOSPOR III study on the investigational microbiome therapeutic SER-109 for the prevention of recurrent C. difficile infection (rCDI). With nearly 156,000 cases in the U.S.

Seres Therapeutics' Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that enrollment in Cohort 2 in its SER-155 Phase 1b study is underway. SER-155, an investigational oral microbiome therapeutic, is designed to reduce the incidence of gastrointestinal (GI) infections, bloodstream infections, and graft versus host disease (GvHD) in individuals undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Today, we take a look at microbiome therapeutic developer Seres Therapeutics, Inc. Seres Therapeutics appears headed to its first FDA approval and has a strategic partnership with Nestlé S.A. around this endeavor.

Seres Therapeutics: FDA Approval Straight Ahead

April 26 is FDA decision day for SER-109, the Seres microbiome treatment for recurrent C. difficile infection. Finch Therapeutics gives up on Phase 3 trial for C. difficile recurrence; lays off 95% of staff.

The Clock Is Ticking For Seres Therapeutics: I'm Not Afraid

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors. Dr. Fraser will begin serving on Seres' Board, effective immediately.

Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D.

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 a.m. PST / 11:15 a.m. EST.

Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host an investor webcast to discuss the planned commercialization approach and market opportunity for therapeutic candidate SER-109 in recurrent C. difficile infection (rCDI) on Thursday, December 8, 2022, at 8:30 a.m. ET and is expected to be approximately one hour in duration.

Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy

After accepting the BLA for SER-109, the FDA has not announced the need for an expert advisory committee. The FDA provides a firm date (April 26, 2023) for its decision concerning approval of SER-109.

Seres Gets Closer To Good Times

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET Company Participants Carlo Tanzi - Head of Investor Relations Eric Shaff - President & Chief Executive Officer Lisa von Moltke - Chief Medical Officer Matthew Henn - Chief Scientific Officer David Arkowitz - Chief Financial Officer Teresa Young - Chief Commercial & Strategy Officer Conference Call Participants Peyton Bohnsack - Cowen Ted Tenthoff - Piper Sandler Mark Breidenbach - Oppenheimer John Newman - Canaccord Operator Good morning. My name is Colby and I will be your conference operator today.

Seres Therapeutics, Inc. (MCRB) Q3 2022 Earnings Call Transcript

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.89% and 71.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates

Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings

Seres Therapeutics' ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association

Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Matthew Henn, Ph.D., Chief Scientific Officer at Seres, will be presenting at the World Anti-Microbial Resistance Congress being held on September 7-8, 2022 in National Harbor, Maryland. Dr. Henn will present at 12:00 p.m. ET today a presentation entitled: “Microbiome Therapeutics to Potentially Transform the Management of Antimicrobial Resistant Infections

Seres Therapeutics to Present at World Anti-Microbial Resistance Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SER-109 for the prevention of recurrent C. difficile infection (rCDI). SER-109 is an entirely new treatment modality that shows promise to improve the current standard of care for rCDI. “Completing this BLA submission mar

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

Seres Therapeutics was founded in 2010 at a time when the Human Microbiome Project was “hot”. So Seres was there when microbiomics began to get serious. Nestle Health Science has been an early investor and concluded a major deal on marketing rights in early 2016. The first product, SER-109, is being readied for market.

Seres Therapeutics: What The Market Is Missing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a discussion at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10 at 12:30 p.m. ET. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website. A replay of the presentation will become available approximately

Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Carlo Tanzi - Head of IR Eric Shaff - President & CEO Lisa von Moltke - Chief Medical Officer Matthew Henn - Chief Scientific Officer David Arkowitz - CFO Terri Young - Chief Commercial and Strategy Officer David Ege - Chief Technology Officer Conference Call Participants Mark Breidenbach - Oppenheimer Peyton Bohnsack - Cowen John Newman - Canaccord Ted Tenthoff - Piper Sandler Chris Howerton - Jeffries Chris Shibutani - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the Q2 2022 Seres Therapeutics, Inc. Earnings Conference Call.

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2022 Results - Earnings Call Transcript

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -20.69% and 79.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported second quarter 2022 financial results and provided business updates. “We made considerable progress on key clinical, corporate and commercial initiatives that bolster our leadership in the microbiome field,” said Eric Shaff, President and Chief Executive Officer at Seres. “We were delighted to report positive confirmatory safety and efficacy data from our SER-109

Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2022, at 8:30 a.m. ET to discuss second quarter 2022 results and provide a general business update. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference conference ID 3171491. To join the live webcast, please visit the “Inve

News for Seres Therapeutics Stock (MCRB)